APC/Cyanine7 anti-human HLA-DR Antibody
Catalog# / Size 307617 / 25 tests
307618 / 100 tests
Clone L243
Other Names Major Histocompatibility Class II, MHC class II
Isotype Mouse IgG2a, κ
Description HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and
a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages,
dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex
and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4 T cells. +
Product Details
Reactivity Human, African Green, Baboon, Chimpanzee, Cynomolgus, Dog (Canine), Marmoset, Rhesus, Squirrel
Monkey, Tamarin
Antibody Type Monoclonal
Host Species Mouse
Formulation Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin
USA).
Preparation The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under
optimal conditions.
Concentration Lot-specific (please contact technical support for concentration and total µg amount, or use our Lookup
tool if you have a lot number.)
Storage & Handling The HLA-DR antibody solution should be stored undiluted between 2°C and 8°C, and protected from
prolonged exposure to light. Do not freeze.
Application FC - Quality tested
Recommended Usage Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric
analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100
µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser Red Laser (633 nm)
Application Notes The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II 
3. Donini M, et al. 2011. Prostate. 72:566. PubMed
4. Reismann M, et al. 2014. J Surg Res. 187:197. PubMed
5. Ohue Y, et al. 2014. Clin Cancer Res. 20:5052. PubMed
6. Teirlinck A, et al. 2015. Infect Immun . 83: 3732-3739. PubMed
7. Kurose K, et al. 2015. Clin Cancer Res. 21: 4327 - 4336. PubMed
8. Vogel S, et al. 2015. Sci Rep. 5: 18308. PubMed
9. Finotti G, et al. 2016. J Leukoc Biol. 99: 107 - 119. PubMed
10. Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed
11. Lundberg K, et al. 2016. PLoS One. 11: 0148838. PubMed
12. Ball M, et al. 2016. PLoS One. 11: 0149600. PubMed
RRID AB_493587 (BioLegend Cat. No. 307617)
AB_493586 (BioLegend Cat. No. 307618)
Antigen Details
Structure Ig superfamily, MHC class II, heterodimeric transmembrane protein, 36 kD heavy and 27 kD light chain
Distribution B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs
Function Peptide presentation
Ligand/Receptor CD3/TCR, CD4
Cell Type Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells, Tregs
Biology Area Immunology, Innate Immunity
Molecular Family MHC Antigens
Antigen References 1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.
Gene ID 3122
3123
Related Protocols
Cell Surface Flow Cytometry Staining Protocol
APC anti-human HLA-DR, FITC anti-human HLA-DR, PE anti-human HLA-DR, PE/Cy5 anti-human HLA-DR, Purified anti-human HLADR,
Biotin anti-human HLA-DR, PE/Cy7 anti-human HLA-DR, Alexa Fluor® 488 anti-human HLA-DR, Alexa Fluor® 647 anti-human HLADR,
Pacific Blue™ anti-human HLA-DR, Alexa Fluor® 700 anti-human HLA-DR, PerCP anti-human HLA-DR, PerCP/Cyanine5.5 antihuman
HLA-DR, Brilliant Violet 605™ anti-human HLA-DR, Brilliant Violet 421™ anti-human HLA-DR, Brilliant Violet 570™ anti-human
HLA-DR, Brilliant Violet 711™ anti-human HLA-DR, Brilliant Violet 785™ anti-human HLA-DR, Brilliant Violet 510™ anti-human HLADR,
Ultra-LEAF™ Purified anti-human HLA-DR, Brilliant Violet 650™ anti-human HLA-DR, Purified anti-human HLA-DR (Maxpar®
Ready), PE/Dazzle™ 594 anti-human HLA-DR, APC/Fire™ 750 anti-human HLA-DR, PE/Fire™ 780 anti-human HLA-DR, TotalSeq™-
A0159 anti-human HLA-DR, TotalSeq™-B0159 anti-human HLA-DR, TotalSeq™-C0159 anti-human HLA-DR, Brilliant Violet 750™ antihuman
HLA-DR
Other Formats
Product Data
Human peripheral blood lymphocytes
were stained with CD19 FITC and HLADR
(clone L243) APC/Cyanine7 (left), or
mouse IgG2a, κ APC/Cyanine7 isotype
control (right) 
For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other
violations that may occur with the use of our products.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website,
www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to
manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written
approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.
Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or
commercial use.
BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587